title: [Research progress of anti-influenza virus agents].
abstract: Influenza is a major threat to millions of people worldwide. Vaccines and antiviral agents are two main options available to reduce the impact of the influenza virus, while anti-influenza agents are the most effective means to prevent the transmission of the highly contagious virus and to treat the epidemics of disease. At present, four anti-influenza agents have been approved by the FDA for the treatment of influenza, including two M2 protein ion channel inhibitors-amantadine and rimantadine and two neuraminidase inhibitors-zanamivir and oseltamivir. Arbidol hydrochloride, launched in Russia, is a potent inhibitor of influenza virus, too. Neuraminidase inhibitors could be classified generally by structure into six different kinds: sialic acid derivatives, benzoic acid derivatives, cyclohexene derivatives, cyclopentane derivatives, pyrrolidine derivatives and natural products. In this paper, recent progress in the research of the action mechanisms and structure-activity relationships of these anti-influenza virus agents were reviewed.
authors.affiliation: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhang
authors.forename: Qing-jie
authors.initials: QJ
authors.lastname: Zhao
authors.forename: Rui-sheng
authors.initials: RS
authors.lastname: Xiong
authors.forename: Jian-feng
authors.initials: JF
authors.lastname: Li
authors.forename: Jing-shan
authors.initials: JS
authors.lastname: Shen
mesh_terms: D000146:Acids, Carbocyclic; D000547:Amantadine / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D003517:Cyclopentanes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006146:Guanidines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D007251:Influenza, Human / Q000188:drug therapy; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D009975:Orthomyxoviridae / Q000187:drug effects*; D053139:Oseltamivir / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D012299:Rimantadine / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D014763:Viral Matrix Proteins / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D053243:Zanamivir / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000086082:Viroporin Proteins; D013440:Sulfides
chemical_list: D000146:Acids, Carbocyclic; D000547:Amantadine; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; D007211:Indoles; D009439:Neuraminidase; D053139:Oseltamivir; D011759:Pyrrolidines; D012299:Rimantadine; D014763:Viral Matrix Proteins; D053243:Zanamivir; C456059:A 315675; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins; C086979:umifenovir; D013440:Sulfides; C414210:peramivir